Antibacterial medicinal chemistry - what can we design for?


Journal

Expert opinion on drug discovery
ISSN: 1746-045X
Titre abrégé: Expert Opin Drug Discov
Pays: England
ID NLM: 101295755

Informations de publication

Date de publication:
09 2020
Historique:
pubmed: 27 5 2020
medline: 14 4 2021
entrez: 27 5 2020
Statut: ppublish

Résumé

The need for new antibacterial agents continues to grow, but success in development of antibiotics in recent years has been limited. To improve the chances that new compounds will progress into clinical trials and beyond, it is vital that we consider as early as possible in the process the various challenges that discoverers and developers of new antibiotics will face. The author looks at the factors that affect medicinal chemistry aimed at providing successful antibacterial agents. Target selection, target inhibition, accumulation in bacteria, and pharmacokinetics are all discussed, with a particular emphasis on how our current understanding should impact design and optimization strategies. From the perspective of a medicinal chemist, the primary question when considering the various aspects of antibacterial drug discovery should be 'what can I design for?' It is important to be aware of the limitations of our understanding, and also the constraints and challenges that arise due to the diversity of the bacteria we try to address. Progress is needed to simplify approval pathways and to increase return on investment for the next generations of clinically useful agents to succeed.

Identifiants

pubmed: 32452235
doi: 10.1080/17460441.2020.1767065
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1005-1013

Auteurs

Alastair L Parkes (AL)

Discovery Chemistry, Evotec (UK) Ltd , Abingdon, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH